Alkermes' LUMRYZ Shows Promise in Idiopathic Hypersomnia Phase 3 Trial

Event summary

  • Alkermes' LUMRYZ met primary endpoint in Phase 3 REVITALYZ study for idiopathic hypersomnia, showing statistically significant improvements in excessive daytime sleepiness (p<0.0001).
  • Study involved 104 participants, with those switched to placebo showing significant symptom worsening compared to those continuing LUMRYZ treatment.
  • Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026, but cannot market LUMRYZ for IH before March 1, 2028 due to a licensing agreement.
  • LUMRYZ is currently approved for narcolepsy but not for idiopathic hypersomnia.

The big picture

Alkermes' positive Phase 3 results for LUMRYZ in idiopathic hypersomnia represent a strategic expansion for the drug beyond its current approval for narcolepsy. The company is positioning itself in a niche market with high unmet need, though regulatory and marketing constraints will shape its near-term commercialization strategy. The success of LUMRYZ in this new indication could significantly bolster Alkermes' portfolio in sleep medicine, a field increasingly focused on precision treatments for rare disorders.

What we're watching

Regulatory Timing
Whether Alkermes can secure FDA approval for LUMRYZ in idiopathic hypersomnia by the end of 2026, despite the marketing restriction until 2028.
Market Potential
The size of the idiopathic hypersomnia market and how LUMRYZ could differentiate itself in a space with limited treatment options.
Competitive Landscape
How Alkermes will position LUMRYZ against existing and emerging therapies for sleep disorders, particularly in the narcolepsy and idiopathic hypersomnia spaces.